参考文献/References:
[1]朱玲玲,张海鹰.超声引导下经皮热消融治疗低风险甲状腺乳头状微小癌的安全性和有效性.解放军医学杂志,2021,46(8):796-801.
[2]刘静思，廖泉.甲状腺微小乳头状癌诊治进展.中国实用外科杂志,2017,37(5):588-590.
[3]Moretti S, Menicali E, Nucci N, et al. Therapy of endocrine disease immunotherapy of advanced thyroid cancer: From bench to bedside. Eur J Endocrinol,2020,183(2):41-55.
[4]殷德涛,余坤.结合2015版ATA指南对甲状腺微小乳头状癌热点问题的探讨.西安交通大学学报(医学版),2018,39(1):1-4.
[5]Soares P, Celestino R, Gaspar da Rocha A,et al. Papillary thyroid microcarcinoma: how to diagnose and manage this epidemic? Int J Surg Pathol,2014,22(2):113-119.
[6]毕长庚.甲状腺微小乳头状癌的外科治疗进展与争议.当代医学,2019,25(4):184-186.
[7]中国抗癌协会甲状腺癌专业委员会(CATO).甲状腺微小乳头状癌诊断与治疗中国专家共识(2016版).中国肿瘤临床,2016,43(10):405-411.
[8]于洋,高明.甲状腺微小乳头状癌外科治疗进展.中国肿瘤临床,2015,42(9):487-490.
[9]Guang Y,Luo Y, Zhang Y, et al. Efficacy and safety of percutaneous ultrasound guided radiofrequency ablation for treating cervical metastatic lymph nodes from papillary thyroid carcinoma. Cancer Res Clin Oncol,2017,143(8):1555-1562.
[10]刘畅,边聪,吴述平.热消融与开放手术治疗甲状腺微小乳头状癌的Meta分析.中国现代医药杂志,2020,22(7):1-5.
[11]吴弢，严宏.甲状腺微小乳头状癌外科治疗进展.中国肿瘤外科杂志,2016,8(30)：203-205.
[12]Ding B, Yu J, Sun W, et al. Surgical safety analysis of retaining the glands in papillary thyroid microcarcinoma. Eur Rev Med Pharmacol Sci,2017,21(2):234-238.
[13]Miyauchi A, Ito Y, Oda H. Insights into the management of papillary microcarcinoma of the thyroid. Thyroid(New York, N.Y.),2018,28(1):23-31.
[14]Ding B, Yu JF, Sun W, Ma NF. Surgical safety analysis of retaining the glands in papillary thyroid microcarcinoma. Eur Rev Med Pharmacol Sci,2017,21(2):234-238.
[15]Li C, Cai YC, Sun RH. Papillary thyroid microcarcinoma: surgery or active surveillance? Cancer Control Treat,2019,32(12):1045-1050.
[16]Ito Y, Uruno T, Nakano K, et al. An observation trial without surgical treatment in patients with papillary microcarcinoma of the thyroid. Thyroid,2003,13(4):381-387.
[17]Haugen BR, Alexander EK, Bible KC, et al.2015 American Thyroid Association management guidelines for adult patient with thyroid nodules and differentiated thyroid cancer. Thyroid,2016,26(1):1-133.
[18]Ito Y, Miyauchi A, Kudo T, et al. Trends in the implementation of active surveillance for lowrisk papillary thyroid microcarcinomas at Kuma Hospital: Gradual increase and heterogeneity in the acceptance of this new management option. Thyroid,2018,28(4):488-495.
[19]Miyauchi A, Kudo T, Ito Y, et al. Natural history of papillary thyroid microcarcinoma: Kinetic analyses on tumor volume during active surveillance and before presentation. Surgery,2019,165(1):25-30.
[20]Ito Y, Miyauchi A, Oda H. Lowrisk papillary microcarcinoma of the thyroid: A review of active surveillance trials. Eur J Surg Oncol,2017,44(3):307-315.
[21]Randle RW, Bushman NM, Orne J, et al. Papillary thyroid cancer: The good and bad of the "good cancer". Thyroid,2017,27(7):902-907.
[22]Wang T, Jiang M, Ren Y, et al. Healthrelated quality of life of community thyroid cancer survivors in Hangzhou, China. Thyroid,2018,28(8):1013-1023.
[23]Haugen BR.2015 American thyroid association management guidelines for adult patient with thyroid nodules and differentiated thyroid cancer: What is new and what has changed? Cancer,2017,123(3):372-381.
[24]Ji L, Wu Q, Gu J, et al. Ultrasoundguided percutaneous laser ablation for papillary thyroid microcarcinoma: A retrospective analysis of 37 patients. Cancer Imaging,2019,19(1):1-8.
[25]董丽琴,王小平,陈奎铭,等.甲状腺结节消融的治疗.临床外科杂志,2017,25(2):158-160.
[26]Cho SJ, Back JH, Chung SR, et al. Longterm results of thermal ablation of benign thyroid nodules: a systematic review and metaanalysis. Endocrinol Metab (Seoul),2020,35(2):339-350.
[27]Trimboli P, Castellana M, Sconfienza LM, et al. Efficacy of thermal ablation in benign nonfunctioning solid thyroid nodule: a systematic review and metaanalysis. Endocrine,2020,67(1):35-43.
[28]Bernardi S, Giudici F, Cesareo R, et al. Fiveyear results of radiofrequency and laser ablation of benign thyroid nodules: a multicenter study from the Italian minimally invasive treatments of the thyroid group. Thyroid,2020,30(12):1759-1770.
[29]Hu K, Wu J, Dong Y, et al. Comparison between ultrasoundguided percutaneous radiofrequency and microwave ablation in benign thyroid nodules. J Cancer Res Ther,2019,15(7):1535-1540.
[30]Choi Y, Jung SL. Efficacy and safety of thermal ablation techniques for the treatment of primary papillary thyroid micro carcinoma: a systematic review and metaanalysis. Thyroid,2020,30(5):720-731.
[31]Yue W, Wang S, Wang B, et al. Ultrasound guided percutaneous microwave ablation of benign thyroid nodules: safety and imaging followup in 222 patients. Eur J Radiol,2013,82(1):11-16.
[32]韩茜,张广,孙辉.超声引导下热消融治疗甲状腺微小乳头状癌研究进展.中国普外基础与临床杂志,2017,24(9):1156-1160.
[33]Lim HK, Cho SJ, Baek JH, et al. USguided radiofrequency ablation for lowrisk papillary thyroid microcarcinoma: Efficacy and safety in a large population. Korean J Radiol,2019,20(12):1653.
[34]Xue J, Teng D, Wang H. Efficacy and safety of ultrasoundguided radiofrequency ablation for papillary thyroid microcarcinoma: A systematic review and metaanalysis. Int J Hyperther,2022,39(1):1300-1309.
[35]Seo YK, Cho SW, Sim JS, et al. Radiofrequency ablation of papillary thyroid microcarcinoma: A 10year followup study. Korean Soc Radiol,2021,82(4):914-922.
[36]Song Q, Gao H, Tian X, et al. Evaluation of ultrasoundguided radiofrequency ablation as a treatment option for papillary thyroid microcarcinoma in the isthmus: A retrospective study. Front Endocrinol (Lausanne),2021,11:599471.
[37]He H, Song Q, Lan Y, et al. Efficacy and safety of ultrasoundguided radiofrequency ablation for lowrisk papillary thyroid microcarcinoma in patients aged 55 years or older: A retrospective study. Int J Hyperther,2021,38(1):604-610.
[38]Wu R, Luo Y, Tang J, et al. Ultrasoundguided radiofrequency ablation for papillary thyroid microcarcinoma: A retrospective analysis of 198 patients. Int J Hyperther,2020,37(1):168-174.
[39]冯娜,黄品同,徐栋,等.甲状腺微小乳头状癌射频消融术与外科手术的比较.介入放射学杂志,2021,30(4):356-360.
[40]Zhao Z, Wu J, Liu X, et al. Insufficient radiofrequency ablation promotes proliferation of residual hepatocellular carcinoma via autophagy. Cancer Lett,2018,421(10):73-81.
[41]Ma B，Wei W，Xu W，et al．Surgical confirmation of incomplete treatment for primary papillary thyroid carcinoma by percutaneous thermal ablation：a retrospective case review and literature review．Thyroid,2018,28(9):1134-1142．
[42]刘新承,郝少龙,陈焕杰,等.甲状腺乳头状癌热消融治疗后再手术11例分析.中华普外科手术学杂志(电子版),2018,12(4):299-301．
[43]中国医师协会甲状腺肿瘤消融治疗技术专家组,中国抗癌协会甲状腺癌专业委员会,中国医师协会介入医师分会超声介入专业委员会,等.甲状腺良性结节、微小癌及颈部转移性淋巴结热消融治疗专家共识(2018 版).中国肿瘤,2018,27(10):768-773.
[44]中国医师协会超声医师分会.甲状腺微小乳头状癌热消融诊疗指征专家共识.中华医学超声杂志(电子版),2019,16(8):571-574.
[45]Zhou J, Yin L, Wei X, et al.2020 Chinese guidelines for ultrasound malignancy risk stratification of thyroid nodules: the CTIRADS.Endocrine,2020,70(2):256-279.
[46]Yeh MW, Bauer AJ, Bernet VA, et al. American Thyroid Association statement on preoperative imaging for thyroid cancer surgery.Thyroid,2015,25(1):3-14.